The Centers for Disease Control and Prevention (CDC) recently shared study results of COVID-19 boosters demonstrate that while they continue to offer strong protection against the omicron variant they decline in effectiveness against severe cases. An early and limited initial finding, the national public agency sought to offer an initial glimpse into booster durability and protection. A Vanderbilt University vaccine expert went on the record on mainstream media that he was disappointed that booster doses waned substantially within four months.
The CDC reported on two key studies including one where the national agency analyzed data from its vaccine safety monitoring systems, v-safe and the Vaccine Adverse Event Reporting System (VAERS). Overall, the CDC reports that persons 18 and over who are vaccinated with the same brand for all doses experience less adverse reactions following the booster dose as compared to after a second dose of the mRNA vaccine. The CDC shared 92% of the VAERS reports “were not considered serious, and headache, fever, and muscle pain were among the most commonly reported reactions.” However, 8% of the reports were thus serious and the agency didn’t provide insight into these. The authors also found that data in the V-safe found “medical care was rarely received after a booster dose.” Again, no specifics were included.
For the second study the CDC analyzed 93,000 hospitalizations and 241,000 emergency department and urgent care visits across 10 states during both the Delta and Omicron waves. In the study population the CDC found about 10% of the people were boosted, while for those hospitalized, over 50% were over the age of 65 years. Vaccine effectiveness against hospitalization equaled 91% during the first couple months post the third dose and remained at 78% at month.
A CNBC report further elaborated on outpatient visits during the omicron wave. While vaccine effectiveness in this category equaled 87% in those individuals that received the booster two months previous, that effectiveness went to 66% in four months. For those hospitalized, vaccine effectiveness was 78%, from a start of 91%, in the fourth month.Subscribe to the Trialsitenews “COVID-19” ChannelNo spam – we promise
Concern in the Air
A Vanderbilt University vaccine expert, Dr. William Schaffner shared his thoughts with the mainstream media channel. Revealing his disappointment Schaffner declared “I’m a little surprised, according to the data, that it’s starting to wane already.” The vaccine expert expected better results suggests CNBC reporting which signals a pivot in the coverage of the pandemic.
Dr. Schaffner expected higher vaccine effectiveness by month 4. Regarding the subject of “durability of booster protection” more research is necessary, suggests Schaffner.